-+ 0.00%
-+ 0.00%
-+ 0.00%

4D Molecular Therapeutics Q1 net loss widens to $68.8 million

PUBT·05/07/2026 20:36:11
Listen to the news
4D Molecular Therapeutics Q1 net loss widens to $68.8 million
  • 4D Molecular Therapeutics posted a Q1 net loss of USD 68.8 million, widening from USD 48.0 million a year earlier; loss per share widened to USD 1.01 from USD 0.86.
  • Revenue rose to USD 3.0 million from no revenue a year earlier, on clinical trial cost sharing and reimbursements from Otsuka.
  • Research and development expense climbed to USD 65.0 million from USD 40.7 million, driven by execution of 4D-150 Phase 3 trials in wet AMD.
  • Cash, cash equivalents and marketable securities fell to USD 458 million as of March 31 from USD 514 million at year-end; cash runway expected into second half of 2028.
  • 4D-150 4FRONT-1 wet AMD Phase 3 randomization completed (N=523) with topline data expected in H1 2027; 4FRONT-2 enrollment completion expected in H2 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605071605PRIMZONEFULLFEED9715634) on May 07, 2026, and is solely responsible for the information contained therein.